Basic Neurosciences · Paper A
Dopaminergic pathways
Dopamine (a brain chemical messenger, or NEUROTRANSMITTERA chemical messenger that nerve cells release to signal to the next cell.Read more →) runs along four separate wiring routes (pathways) in the brain. Antipsychotic drugs block dopamine everywhere at once, so they help the intended pathway but also cause side effects in the other three. For example, imagine a patient started on haloperidol for psychosis who then develops a tremor and stiffness. In practice, this means that tremor is an unavoidable side effect of blocking the nigrostriatal pathwayA dopamine brain pathway that controls movement, whose blockade by antipsychotics causes Parkinson's-like side effects.Read more →, not a sign the drug is failing.
MESOLIMBIC pathwayA dopamine brain pathway linked to reward and motivation, and to the positive symptoms of psychosis.Read more → (ventral tegmental areaA midbrain structure that is a key source of the brain's dopamine reward pathways.Read more → (VTA, a midbrain structure) to nucleus accumbensA brain structure central to reward and motivation, heavily involved in addiction.Read more →): drives reward and positive psychotic symptoms such as hallucinationsSeeing, hearing, or otherwise sensing things that are not really there.Read more → (false perceptions with no real stimulus) and delusionsA fixed false belief, held with total conviction, that is not shared by the person's culture and is not changed by evidence against it.Read more →, the pathway antipsychotics are meant to block. MESOCORTICAL pathway (VTA to prefrontal cortexThe front part of the brain responsible for planning, judgement and controlling impulses.Read more →): under-activity here is linked to negative symptoms (apathy, blunted emotion) and cognitive symptoms. NIGROSTRIATAL pathwayA dopamine brain pathway that controls movement, whose blockade by antipsychotics causes Parkinson's-like side effects.Read more → (substantia nigraA deep brain structure rich in dopamine cells whose loss causes Parkinson's disease.Read more → to dorsal striatum, both movement-control structures): blocking it causes drug-induced parkinsonism, tremor, stiffness, slowed movement. TUBEROINFUNDIBULAR pathwayA dopamine brain pathway that normally restrains prolactin release, whose blockade by antipsychotics raises prolactin.Read more → (hypothalamusA small brain structure that controls basic functions like hunger, temperature, sleep and hormone release.Read more → to pituitary gland): dopamine here normally holds down the hormone prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more →, so blocking it lets prolactin rise, causing galactorrhoea (unexpected breast milk) and amenorrhoea (periods stopping). For example, imagine a woman on an antipsychotic who develops unexpected breast milk and missed periods. In practice, this means checking a prolactin level, since blocking the tuberoinfundibular pathway is the likely cause.
Vignette says patient on antipsychotic → identify the side-effect → look up the pathway. EPSE (tremor, rigidity, bradykinesia) = nigrostriatal. Raised prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more → (galactorrhoea, amenorrhoea, sexual dysfunction) = tuberoinfundibular. Worsened negative symptoms = mesocortical. The therapeutic antipsychotic effect = mesolimbic.
The mesolimbic and mesocortical pathways both originate in the VTA — students conflate them. The nigrostriatal originates in the substantia nigraA deep brain structure rich in dopamine cells whose loss causes Parkinson's disease.Read more →, not the VTA. Tuberoinfundibular is in the hypothalamusA small brain structure that controls basic functions like hunger, temperature, sleep and hormone release.Read more → itself. Blocking DA anywhere raises prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more → in the pituitary is wrong — only blockade in the tuberoinfundibular pathwayA dopamine brain pathway that normally restrains prolactin release, whose blockade by antipsychotics raises prolactin.Read more → raises prolactin.
Step 1Identify the EFFECT from the vignette (motor, prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more →, psychosis reduction, cognitive). Step 2 – Map effect→pathway: motor=nigrostriatal, prolactin=tuberoinfundibular, psychosis=mesolimbic, cognitive=mesocortical. Step 3 – If asked what happens with blockade, apply the 1:1 rule. Works for any antipsychotic and any presentation variant.
Every antipsychotic drug works by blocking dopamine (a brain chemical messenger, or ), but dopamine does not do one job in one place — it runs along four separate wiring routes called PATHWAYS, and each pathway does something completely different. This single fact explains almost every antipsychotic side effect a clinician will ever be asked about: the drug cannot aim at just one pathway, so treating the intended target always means disturbing the other three at the same time. For example, imagine a patient started on haloperidol for psychosis who a few days later develops a tremor and stiff limbs — that is not the drug failing, it is the predictable result of blocking a completely different pathway from the one treating the psychosis.
A pathway is simply a bundle of dopamine-releasing nerve fibres running from one brain region, its ORIGIN, to another, its TARGET. Blocking dopamine at the target is what an antipsychotic actually does pharmacologically, so the clinical effect of that blockade depends entirely on which target is involved, not on the drug itself, which blocks dopamine everywhere in the brain in roughly the same way.
The single biggest trap is treating 'blocking dopamine' as one uniform action with one uniform consequence. It is not: two of the four pathways share the same starting point but produce opposite symptom patterns, while the other two start somewhere else entirely and control movement and hormones, not mood. A real patient, or an exam vignette, can show effects from more than one pathway at once, and conflating them is the single most common error on this topic.
Picture the brain's dopamine system as four separate cables running out from two control rooms. Two cables, the mesolimbic and mesocortical routes, both originate in the (VTA, a midbrain structure) but run to different destinations, and — this is the counter-intuitive part — they have OPPOSITE relationships with psychotic symptoms. The other two cables, nigrostriatal and tuberoinfundibular, start in completely different structures, the and the , and have nothing to do with mood at all: one governs movement, the other governs a single hormone. An antipsychotic tablet cannot choose which cable to block; it floods the whole system at once, so knowing WHERE each cable starts and ends is what predicts every side effect that follows.
MESOLIMBIC (VTA to , the brain's reward hub): over-activity here drives the POSITIVE symptoms of psychosis, (false perceptions with no real stimulus, for example hearing voices) and (fixed false beliefs held despite clear contrary evidence). This is the pathway antipsychotics are actually meant to block, and dampening it is what reduces hallucinations and delusions.
MESOCORTICAL (VTA to prefrontal cortex, the front-of-brain region responsible for planning and drive): here the problem runs the opposite direction. UNDER-activity is linked to the NEGATIVE symptoms of psychosis (apathy, blunted emotion, social withdrawal) and to poor concentration. A drug that blocks dopamine to calm the mesolimbic pathway can worsen an already under-active mesocortical pathway at the same time, creating a genuine therapeutic tension between the two VTA-origin pathways.
NIGROSTRIATAL ( to dorsal striatum, both movement-control structures): this pathway's normal job is smooth, coordinated movement, so blocking it produces drug-induced parkinsonism, tremor, rigidity (stiffness), and bradykinesia (slowed movement), together called the extrapyramidal side effects (EPSE). This is the same pathway that degenerates naturally in Parkinson's disease.
TUBEROINFUNDIBULAR ( to pituitary gland): dopamine here normally acts as a brake, continuously holding down the hormone . Block that brake and prolactin rises, , producing galactorrhoea (unexpected breast-milk production) and amenorrhoea (periods stopping), and over time reduced bone density and libido.
Mesolimbic and mesocortical effects are easy to confuse because both originate in the VTA; the discriminator is the symptom direction, not the structure. Positive symptoms improving points to mesolimbic blockade doing its job, while negative symptoms worsening points to mesocortical blockade as an unwanted side effect. Nigrostriatal and tuberoinfundibular effects are discriminated by symptom TYPE rather than shared anatomy: tremor and rigidity point to the movement pathway, while unexpected lactation and missed periods point to the hormone pathway, and a patient can genuinely have both together, since typical antipsychotics block both routes roughly as hard as each other.
There is no scan or blood test that identifies which dopamine pathway is responsible for a psychotic symptom itself; psychosis remains a clinical diagnosis built on history and mental state examination. But once an antipsychotic is started, the pathway-specific side effects do have concrete confirmatory steps: suspected tuberoinfundibular blockade is confirmed with a serum level, and suspected nigrostriatal blockade, drug-induced parkinsonism, is diagnosed clinically by examining tone, gait and tremor, since imaging adds nothing over a careful motor examination in this context.
Older TYPICAL (first-generation) antipsychotics such as haloperidol block dopamine tightly and indiscriminately, hitting the nigrostriatal and tuberoinfundibular routes hard and producing high rates of EPSE and raised . Newer ATYPICAL (second-generation) antipsychotics are designed to bind more loosely or briefly at those two off-target receptor sites, cutting movement and hormone side effects while still blocking the enough to control psychosis. NICE and the Maudsley Prescribing Guidelines both build their antipsychotic-choice recommendations around exactly this trade-off, weighing side-effect burden as heavily as symptom control when choosing between agents. Established EPSE is managed with dose reduction or a switch to a more sparing atypical agent; established is managed the same way, guided by a repeat prolactin level to confirm improvement.
A question testing this topic will hand you either the anatomy, a named structure like the VTA or the , or the clinical effect, a symptom like tremor or galactorrhoea, and expect you to supply the other half, often placing two pathways in the very same vignette to catch a candidate who only memorised one direction. Remember the VTA gives rise to TWO pathways with opposite symptom links, so naming 'VTA' alone never answers the question; you must also say which of its two destinations, and therefore which symptom pattern, is meant.
Mesolimbic over-activity gives positive symptoms, the antipsychotic's actual target, mesocortical under-activity gives negative and cognitive symptoms, nigrostriatal blockade gives parkinsonism and EPSE, and tuberoinfundibular blockade releases the brake on , so one drug produces one intended effect plus three predictable side-effect risks.